Elahe Seyed Hosseini1, Narjes Riahi Kashani2, Hossein Nikzad3, Javid Azadbakht4, Hassan Hassani Bafrani5, Hamed Haddad Kashani6. 1. Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: elaheir.66@gmail.com. 2. Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: riahir@yahoo.com. 3. Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: nikzad.kaums@gmail.com. 4. Department of Radiology, Faculty of Medicin, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: javidazadbakht2@gmail.com. 5. Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: hassanibafrani.h@gmail.com. 6. Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: hamedir2010@gmail.com.
Abstract
Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β-coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously. Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.
Novel coronavirusn class="Species">SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β-coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously. Currently, antiviral inhibitors of SARS and MERSspike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs withtheir effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.
Authors: Sabue Mulangu; Lori E Dodd; Richard T Davey; Olivier Tshiani Mbaya; Michael Proschan; Daniel Mukadi; Mariano Lusakibanza Manzo; Didier Nzolo; Antoine Tshomba Oloma; Augustin Ibanda; Rosine Ali; Sinaré Coulibaly; Adam C Levine; Rebecca Grais; Janet Diaz; H Clifford Lane; Jean-Jacques Muyembe-Tamfum; Billy Sivahera; Modet Camara; Richard Kojan; Robert Walker; Bonnie Dighero-Kemp; Huyen Cao; Philippe Mukumbayi; Placide Mbala-Kingebeni; Steve Ahuka; Sarah Albert; Tyler Bonnett; Ian Crozier; Michael Duvenhage; Calvin Proffitt; Marc Teitelbaum; Thomas Moench; Jamila Aboulhab; Kevin Barrett; Kelly Cahill; Katherine Cone; Risa Eckes; Lisa Hensley; Betsey Herpin; Elizabeth Higgs; Julie Ledgerwood; Jerome Pierson; Mary Smolskis; Ydrissa Sow; John Tierney; Sumathi Sivapalasingam; Wendy Holman; Nikki Gettinger; David Vallée; Jacqueline Nordwall Journal: N Engl J Med Date: 2019-11-27 Impact factor: 91.245
Authors: Timothy P Sheahan; Amy C Sims; Rachel L Graham; Vineet D Menachery; Lisa E Gralinski; James B Case; Sarah R Leist; Krzysztof Pyrc; Joy Y Feng; Iva Trantcheva; Roy Bannister; Yeojin Park; Darius Babusis; Michael O Clarke; Richard L Mackman; Jamie E Spahn; Christopher A Palmiotti; Dustin Siegel; Adrian S Ray; Tomas Cihlar; Robert Jordan; Mark R Denison; Ralph S Baric Journal: Sci Transl Med Date: 2017-06-28 Impact factor: 17.956
Authors: Silvana Konermann; Peter Lotfy; Nicholas J Brideau; Jennifer Oki; Maxim N Shokhirev; Patrick D Hsu Journal: Cell Date: 2018-03-15 Impact factor: 41.582
Authors: Maria L Agostini; Erica L Andres; Amy C Sims; Rachel L Graham; Timothy P Sheahan; Xiaotao Lu; Everett Clinton Smith; James Brett Case; Joy Y Feng; Robert Jordan; Adrian S Ray; Tomas Cihlar; Dustin Siegel; Richard L Mackman; Michael O Clarke; Ralph S Baric; Mark R Denison Journal: mBio Date: 2018-03-06 Impact factor: 7.867
Authors: Jiumeng Sun; Wan-Ting He; Lifang Wang; Alexander Lai; Xiang Ji; Xiaofeng Zhai; Gairu Li; Marc A Suchard; Jin Tian; Jiyong Zhou; Michael Veit; Shuo Su Journal: Trends Mol Med Date: 2020-03-21 Impact factor: 11.951